Intestinal Organoids
Recruiting · NCT05294107 · Interventional (participants receive a specific treatment) · Lead sponsor: Rennes University Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Over the last decade, the use of mini-organ or organoids has been increasingly developed in fundamental research. Indeed, digestive organoids represent an essential advance compared to classical culture systems (epithelial cell lines, immortalized cells) since they preserve in culture the functional complexity present in vivo (architecture, different cell types). They also have the advantage of being able to be propagated indefinitely (unlike explants), minimizing the use of animal models and reducing the amount of tissue required. Finally, their growth and development depends on the origin of the sample (the organoid will develop differently if the cell source comes from a patient suffering from an inflammatory bowel disease, for example), thus generating models of human pathologies to better determine their physiopathology. The use of organoids in biomedical research has proven to be an indispensable tool for the understanding of cellular and molecular mechanisms involved in epithelial renewal and the screening of molecules and ingredients for applications in the health and agri-food sectors.
Who can take part
Inclusion criteria
- Subjects aged 18 to 75 years
- Subject undergoing endoscopy as part of the standard of care with the need to take digestive biopsy samples
- Subject having signed a free and informed consent in writing
Exclusion criteria
- Subjects under legal protection (safeguard of justice, curatorship or guardianship) or deprived of liberty.
- Anticoagulant treatment and anti-platelet treatment (except for aspirin 75 mg)
Where it is running
2 locations listed.
- CHU de RENNES-Service des Maladies de l'Appareil Digestif - Rennes, France
- CHU de RENNES-Service des Maladies de l'Appareil Digestif - Rennes, France